Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position
摘要:
Novel 2,4,5-trisubstituted imidazole derivatives were prepared as potential anticytokine agents. Thirty-seven compounds were tested on their ability to inhibit the release of tumor necrosis factor-a (TNF-alpha and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) or human whole blood. SARs (structure activity relationships) for substituents-at the 4 and 5 position of the imidazole core were similar to those described for other inhibitors of cytokine. release and p38 MAP (mitogen-activated protein) kinase. Starting from benzylsulfanyl imidazole 2b (IC50 p(38), 4.0 muM; TNF-alpha, 1.1,muM; IL-1beta, 0.38,muM), the contribution of substituents at the 2 Position to enzyme inhibitory and cellular activity of test compounds was investigated. This strategy led to the identification of compound 2q (IC50 p38, 0.63 muM; TNF-alpha, 0.90 muM; IL-1beta, 0.04,muM), which was 6-10 times more potent than the initial lead 2b with respect to inhibition of p38 and IL-1beta release and equipotently inhibited TNF-alpha release.
Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position
摘要:
Novel 2,4,5-trisubstituted imidazole derivatives were prepared as potential anticytokine agents. Thirty-seven compounds were tested on their ability to inhibit the release of tumor necrosis factor-a (TNF-alpha and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) or human whole blood. SARs (structure activity relationships) for substituents-at the 4 and 5 position of the imidazole core were similar to those described for other inhibitors of cytokine. release and p38 MAP (mitogen-activated protein) kinase. Starting from benzylsulfanyl imidazole 2b (IC50 p(38), 4.0 muM; TNF-alpha, 1.1,muM; IL-1beta, 0.38,muM), the contribution of substituents at the 2 Position to enzyme inhibitory and cellular activity of test compounds was investigated. This strategy led to the identification of compound 2q (IC50 p38, 0.63 muM; TNF-alpha, 0.90 muM; IL-1beta, 0.04,muM), which was 6-10 times more potent than the initial lead 2b with respect to inhibition of p38 and IL-1beta release and equipotently inhibited TNF-alpha release.
2-arylalkylthio -imidazoles, 2-arylalkenyl -thio -imidazoles and 2-arylalkinyl -thio -imidazoles as anti -inflammatory substances and substances inhibiting the release of cytokine
申请人:Merckle GmbH
公开号:US06432988B1
公开(公告)日:2002-08-13
The invention relates to 4-heteroaryl-5-phenylimidazole derivatives having 2-arylalkylthio, 2-arylalkenylthio and 2-arylalkynylthio substitution, of the general formula I:
in which Ar is a phenyl radical, Het is a hetero aromatic radical, A is an alkylene chain, R1 is an alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamido or alkylcarbonyl group and R2 is an alkyl, hydroxyl, alkoxy, alkoxycarbonyl, sulfonamido, carboxyl, nitro or aminocarbonyl group or a halogen atom. n can be 1 or 2 and m is 0 to 2. The compounds according to the invention show antiinflammatory activity.
[DE] 2-THIO-SUBSTITUIERTE IMIDAZOLDERIVATE UND IHRE VERWENDUNG IN DER PHARMAZIE<br/>[EN] 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS<br/>[FR] DERIVES D'IMIDAZOL 2-THIO-SUBSTITUES ET LEUR UTILISATION DANS LE DOMAINE PHARMACEUTIQUE
申请人:MERCKLE GMBH
公开号:WO2004018458A1
公开(公告)日:2004-03-04
Die Erfindung betrifft 2-Thio-substituierte Imidazolderivate der Formel (I) worin die Reste R1, R2, R3 und m die in der Beschreibung angegebene Bedeutung besitzen. Die erfindungsgemässen Verbindungen besitzen eine immunmodulierende und/oder die Cytokinfreisetzung hemmende Wirkung und sind daher geeignet zur Behandlung von Erkrankungen, die mit einer Störung des Immunsystems im Zusammenhang stehen.
2-Thio-substituted imidazole derivatives and their use in pharmaceutics
申请人:Laufer Stefan
公开号:US20060235054A1
公开(公告)日:2006-10-19
The invention relates to 2-thio-substituted imidazole derivatives of the formula I
in which the radicals R
1
, R
2
R
3
and m are as defined in the description. The compounds according to the invention have immunomodulating and/or cytokine-release-inhibiting action and are therefore suitable for treating disorders associated with a disturbed immune system.
2-ARYLALKYLTHIO -IMIDAZOLE, 2-ARYLALKENYL -THIO -IMIDAZOLE UND 2-ARYLALKINYL -THIO -IMIDAZOLE ALS ENTZÜNDUNGS -HEMMSTOFFE UND HEMMSTOFFE DER CYTOKIN -FREISETZUNG
申请人:MERCKLE GMBH
公开号:EP1112265A1
公开(公告)日:2001-07-04
2-THIO-SUBSTITUIERTE IMIDAZOLDERIVATE UND IHRE VERWENDUNG IN DER PHARMAZIE